Identifying specific genomic alterations, such as mutations, amplifications, or fusions, helps identify potential therapeutic targets that assist oncologists in selecting the most appropriate targeted therapies for individual patients, increasing the likelihood of treatment success.

Certain genetic alterations can influence the prognosis of cancer patients, such as indicating a higher likelihood of disease recurrence or metastasis. This gene panel helps oncologists better understand the patient’s disease trajectory and tailor their management strategies by identifying these prognostic biomarkers.

This gene panel is designed to make cancer biomarker testing affordable and accessible for all cancer patients. The test optimizes cost without compromising the essential genes for analysis. This affordability enables a broader population of patients to benefit from genomic profiling and personalized treatment approaches, ultimately improving patient outcomes.

This gene panel utilizes a combined NGS approach that includes solid and liquid biopsy samples. This approach enhances the resolution of the disease genomic landscape by leveraging the strengths of each sample source.